Table 5.
Hematological value of female rats treated with GlucoMedix® at 28 days
| Group/dose (mg/kg) | HCT (%) | HGB (g/dl) | WBC Differential Counting | RBC x106cell/ul | WBC x103cell/ul | |||
|---|---|---|---|---|---|---|---|---|
| NEU | MONO | EOS | LYM | |||||
| % | (%) | (%) | (%) | |||||
| 250 | 41.06 ± 1.14 | 13.66 ± 0.44 | 60.2 ± 1.64 | 4.60 ± 1.14 | 2.80 ± 0.84 | 31.00 ± 3.08 | 4.46 ± 0.27 | 6.26 ± 0.23 |
| 1000 | 42.98 ± 3.61 | 13.70 ± 0.34 | 58.00 ± 2.55 | 4.80 ± 1.30 | 2.40 ± 0.55 | 34.80 ± 2.95 | 4.92 ± 0.24 | 6.10 ± 0.19 |
| 2000 | 43.24 ± 0.42 * | 14.48 ± 0.53 | 60.20 ± 1.10 | 4.20 ± 1.30 | 2.60 ± 0.55 | 29.80 ± 4.60 | 4.70 ± 0.32 | 6.08 ± 0.24 |
| Control | 40.08 ± 0.80 | 13.32 ± 0.51 | 60.40 ± 1.14 | 4.40 ± 0.89 | 2.60 ± 0.55 | 31.60 ± 2.07 | 4.64 ± 0.32 | 6.08 ± 0.22 |
Values are expressed as mean ± SD. n = 5. Parameters include hematocrit (HCT), hemoglobin (HGB), neutrophils (NEU), monocytes (MON), eosinophils (EOS), lymphocytes (LYM), red blood cells (RBC), and white blood cells (WBC). * p < 0.05 compared to control group